Month: September 2020

September 17, 2020Announcement no. 16BioPorto plans initial clinical evaluation of gRAD-based test for rapid detection of COVID-19 virusDevelopment of a rapid point-of-care test for COVID-19 advances towards goal of requesting EUA and CE Mark in 2020BioPorto Diagnostics A/S (BioPorto) and the University of Southern Denmark (SDU) announced in April 2020 a fast-track collaboration to create a rapid test for SARS-CoV-2, the virus that causes COVID-19. Leveraging SDU’s antibody expertise and BioPorto’s Generic Rapid Assay Device (gRAD) platform for the development of lateral flow assays, the collaboration envisioned developing an instrument-free, simple solution to test patients for SARS-CoV-2. Designed to provide a qualitative result in under 10 minutes from a minimally invasive sample, and to be easily administered at the point of care,...

17 September 2020Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.SATO CorporationPre-stabilisation Period AnnouncementDanske Bank A/S (contact: Syndicate – Morten Grove; telephone: + 45 45 14 70 33) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Delegated Regulation (EU) 2016/1052 under the Market Abuse Regulation (EU/596/2014).In connection with the offer of the above securities, the Stabilisation Manager(s) may over‑allot the securities or effect transactions with a view to supporting the market price of the securities during the stabilisation period at a level higher than that which might otherwise prevail. However,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON LOCATED OR RESIDENT IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFULOR REQUIRE REGISTRATION OR ANY OTHER MEASURES. THIS COMPANY ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR BUY ANY OF THE SECURITIES DESCRIBED HEREIN.Company Announcement no. 13/2020 (17.09.2020)Reference is made to Company Announcement no. 10/2020 and 12/2020 regarding the announcement and successful completion of a written procedure initiated by European Energy A/S (the “Company“) to amend the terms and conditions of the Company’s outstanding EUR 200,000,000 Senior Secured Callable Floating Rate Green Bonds...

Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed to fast-track growth.20+ portfolio companies that represent pillars of the future economy: digital health and diagnostics, artificial intelligence (AI), machine learning (ML), augmented and virtual reality (AR and VR), internet of things (IOT), cyber security, blockchain and more.VST ended the quarter with a strong balance sheet with $1,683,991 in cash and cash equivalents. The Company also has access to a $10,000,000 convertible note for operational and growth capital.VANCOUVER, British Columbia, Sept. 17, 2020 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that builds and invests in cutting-edge technology that is shaping...

Data is part of Genentech’s MORPHEUS umbrella program and covers patients with resistant/refractory NSCLC treated with ciforadenant in combination with atezolizumabResults consistent with prior studies, showing prolonged survival compared to chemotherapy and favorable safety dataBURLINGAME, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new data from its clinical collaboration with Genentech, which is being conducted under Genentech’s MORPHEUS umbrella program, will be presented in a poster presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which is taking place September 19-21, 2020. The poster was made available online today 9:00 am CEST (3:00 am ET) as part of the pre-release of e-Posters.“In...

Step-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit to PD-1 inhibitor therapy100% of patients have immune responses to ATLAS-identified neoantigensCAMBRIDGE, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presents additional clinical response and immunogenicity data from the first five patients vaccinated in Part B of the ongoing GEN-009 Phase 1/2a trial at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.ESMO E-POSTER PRESENTATION:Poster 1028P Title: Preliminary results of a pilot trial of GEN-009, a neoantigen vaccine containing immunogenic tumor specific neoantigens, in combination with PD-1 inhibitors in advanced...

DNA PLC STOCK EXCHANGE RELEASE 17 SEPTEMBER 2020 10:00 am (EEST)Timo Karppinen, DNA’s CFO and a member of the DNA Executive Team, has resigned to take on new challenges outside DNA.The search for a new Chief Financial Officer will be started immediately. Karppinen will continue in his current position and as a member of the DNA Executive Team until the end of January 2021.“Timo has played a key role in DNA for almost eight years, during which time DNA listed on the stock exchange and has significantly increased its value as a company. I thank Timo warmly for his contribution and I wish him success in all his future endeavours,” says Jukka Leinonen, DNA’s CEO.Further information: Jukka Leinonen, CEO, DNA Plc, tel. +358 44 044 1000, jukka.leinonen@dna.fi DNA Corporate Communications, tel. +358 44 044 8000, communicati...

DNA OYJ PÖRSSITIEDOTE 17.9.2020 KLO 10.00DNA:n talous- ja rahoitusjohtaja sekä johtoryhmän jäsen Timo Karppinen on irtisanoutunut tehtävästään siirtyäkseen uusien haasteiden pariin DNA:n ulkopuolelle.Uuden talous- ja rahoitusjohtajan haku käynnistetään välittömästi. Karppinen jatkaa nykyisessä tehtävässään ja johtoryhmän jäsenenä tammikuu 2021 loppuun saakka.”Timo on toiminut avainasemassa DNA:lla liki kahdeksan vuotta, minkä aikana DNA on muun muassa listautunut pörssiin ja on nostanut arvoaan yrityksenä merkittävästi. Kiitän Timoa lämpimästi hänen työpanoksestaan ja toivotan menestystä myös jatkossa”, DNA:n toimitusjohtaja Jukka Leinonen kommentoi.Lisätietoja medialle:toimitusjohtaja Jukka Leinonen, DNA Oyj, puh. 044 044 1000, jukka.leinonen@dna.fi DNA:n viestintä, puh. 044 044 8000, viestinta@dna.fi 

Press Release17 September 2020Immunicum AB (publ) Presents Preclinical Data on Ilixadencel in Combination with Cancer Therapies and Immunotherapies at the 2020 Virtual ESMO CongressImmunicum AB (publ: IMMU.ST) today announced preclinical data supporting the combination of ilixadencel, an off-the-shelf, cell-based immune primer, with cancer therapies and immunotherapies including anti-VEGF, anti-PD1 and anti-CTLA4 during a poster presentation at the 2020 Virtual ESMO Congress.Earlier communicated results from preclinical studies in mice demonstrated that animals treated with the combination of ilixadencel and anti-CTLA4 showed a stronger anti-tumor response as compared to animals treated with anti-PD1 and anti-CTLA4, a potent and marketed combination of checkpoint inhibitors. Following the completion of additional experiments, Immunicum...

Pressmeddelande17 september 2020Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med cancerbehandlingar och immunterapier på årets ESMO-kongressImmunicum AB (publ; IMMU.ST) meddelar idag prekliniska data som stöder kombinationen av ilixadencel, en cellbaserad lagringsbar immunaktiverare, med cancerbehandlingar och immunterapier inklusive anti-VEGF, anti-PD1 och anti-CTLA4 under en posterpresentation på årets ESMO-kongress (ESMO Virtual Congress 2020).Tidigare kommunicerade resultat från prekliniska studier på möss har visat att djur som behandlats med kombinationen av ilixadencel och anti-CTLA4 lett till en starkare anti-tumörrespons jämfört med djur som behandlades med anti-PD‑1 och anti-CTLA4, en väletablerad kombination av checkpointhämmare. Efter att ha genomfört ytterligare studier har Immunicum kunnat...